InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,282.70
(
0.13%
)
US TECH 100
17,825.60
(
0.33%
)
Dow Jones
39,142.23
(
-1.33%
)
Brent Oil
66.14
(
-1.40%
)
Bitcoin
87,296.99
(
2.48%
)
Post# of 255132
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (4) Keep Next 10 Report Keyboard Shortcuts
Replies (4) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 840
Posts 121462
Boards Moderated 8
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 239626

Saturday, 03/19/2022 1:37:44 PM

Saturday, March 19, 2022 1:37:44 PM

Post# of 255132
FDA approves BMY’s Opdualag—a_co-formulated_FDC_of Opdivo and anti-LAG-3 relatlimab—in first-line melanoma:

https://finance.yahoo.com/news/u-food-drug-administration-approves-222900124.html

The approval is based on the RELATIVITY-047 trial, which tested Opdivo + relatlimab against Opdivo monotherapy and had a PFS HR=0.75 (#msg-163914232).

In first-line melanoma, Opdulag offers comparable efficacy to Opdivo + Yervoy with less toxicity.

My abbreviated take:
https://twitter.com/DewDiligence/status/1395141087413538822

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (4) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (4) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up